AK03 personal page - To The Moon

AK03

No personal profile

5Follow

2Followers

0Topic

0Badge

2021-09-12

Ohhh

@AK03:Ok

2021-07-30

Hmm

Sorry, the original content has been removed

2021-07-29

Ok

Sorry, the original content has been removed

2021-07-28

Ok

Sorry, the original content has been removed

2021-07-27

Ok

Sorry, the original content has been removed

2021-07-22

Hmm

Sorry, the original content has been removed

2021-07-20

I see....

3 Expensive Stocks I'd Sell Before the Next Market Crash

2021-07-20

Ok

3 Areas Where Pfizer Is Crushing Moderna

2021-07-19

Ok

Morgan Stanley: This Cycle Will Be "Hotter But Shorter" Than Usual

2021-07-18

Latest

US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3573200239055289,"uuid":"3573200239055289","gmtCreate":1610115786867,"gmtModify":1610115786867,"name":"AK03","pinyin":"ak03","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":5,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":888919421,"gmtCreate":1631420777963,"gmtModify":1676530545503,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ohhh","listText":"Ohhh","text":"Ohhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":17,"repostSize":0,"link":"https://ttm.financial/post/888919421","repostId":"809890840","repostType":1,"repost":{"id":809890840,"gmtCreate":1627355930980,"gmtModify":1703488271587,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809890840","repostId":"2154964378","repostType":4,"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808748076,"gmtCreate":1627612773295,"gmtModify":1703493371821,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":14,"repostSize":0,"link":"https://ttm.financial/post/808748076","repostId":"2155188062","repostType":4,"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808883150,"gmtCreate":1627568744270,"gmtModify":1703492597045,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":10,"repostSize":0,"link":"https://ttm.financial/post/808883150","repostId":"1191327663","repostType":4,"isVote":1,"tweetType":1,"viewCount":822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801068405,"gmtCreate":1627474294307,"gmtModify":1703490627200,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":22,"repostSize":0,"link":"https://ttm.financial/post/801068405","repostId":"1141827079","repostType":4,"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809890840,"gmtCreate":1627355930980,"gmtModify":1703488271587,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":33,"repostSize":1,"link":"https://ttm.financial/post/809890840","repostId":"2154964378","repostType":4,"isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172899134,"gmtCreate":1626948477928,"gmtModify":1703481142037,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":22,"repostSize":0,"link":"https://ttm.financial/post/172899134","repostId":"1149385054","repostType":4,"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178116172,"gmtCreate":1626791499196,"gmtModify":1703765323314,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I see....","listText":"I see....","text":"I see....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":15,"repostSize":0,"link":"https://ttm.financial/post/178116172","repostId":"2152693458","repostType":4,"repost":{"id":"2152693458","pubTimestamp":1626790560,"share":"https://www.laohu8.com/m/news/2152693458?lang=&edition=full","pubTime":"2021-07-20 22:16","market":"us","language":"en","title":"3 Expensive Stocks I'd Sell Before the Next Market Crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2152693458","media":"Motley Fool","summary":"Even if you love these stocks, it may not be a bad move to cash out right now.","content":"<p>The stock market has been soaring to new heights in recent weeks and months, even though the coronavirus persists in some places, the economy hasn't fully recovered, and stimulus payments are still propping things up. All this creates a risk that as things get back to normal, the market overall could be due for a correction. Some of the money that has been flowing into it could be cashed out and put back into bonds as interest rates rise, or used for other purposes as spending resumes and people choose to hold less in stocks.</p>\n<p>If I owned <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna, Inc.</a></b> , <b><a href=\"https://laohu8.com/S/FUBO\">fuboTV Inc.</a></b>, or <b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b>, I'd be considering selling them right now. Each company's share prices has more than doubled in the past year, blowing past the <b>S&amp;P 500</b> and its 35% gains during that time. But with inflated valuations and the possibility of a crash looming, they become riskier as each day passes by.</p>\n<p><img src=\"https://static.tigerbbs.com/f1da2df5b21cc39ab7b17f7b776e5045\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. Moderna</h3>\n<p>Moderna has soared by 250% in 12 months, and for good reason -- its COVID-19 vaccine obtained emergency use authorization from the U.S. Food and Drug Administration (FDA) last year. The company expects to generate more than $18 billion in revenue from the vaccine in 2021, and its bottom line will finally be in the black -- in 2020 its losses totaled $747 million, triple what it lost in 2017.</p>\n<p>Things are certainly looking up for Moderna, especially with rival&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> looking to get the OK from the FDA for a third dose of its vaccine to help fight the delta variant. If Pfizer is successful, it's likely Moderna would follow suit, which could bring in even more revenue for the company. But there's no certainty that will happen. And more vaccines could be coming to market soon, including <a href=\"https://laohu8.com/S/AONE.U\">one</a> from <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>, which plans to apply for authorization from the FDA during the third quarter.</p>\n<p>As countries have more options for vaccines, that will inevitably bring down the revenue and potential market share for Moderna. And beyond that, there are questions about what the future holds for Moderna after COVID-19. While its mRNA technology has proven to be effective, that doesn't guarantee that other vaccines in its pipeline will succeed. Its vaccine for cytomegalovirus, currently the furthest along, is entering phase 3 trials. With a peak annual revenue potential of between $2 billion and $5 billion, however, the company won't be able to solely rely on it in replacing COVID-19-related revenue.</p>\n<p>Moderna's future is a question mark for me, and while its forward price-to-earnings ratio of 11 looks cheap, that could change drastically post-COVID. Even on a forward basis, the stock is trading at more than 6 times revenue -- Pfizer is at just 3. Although Moderna is doing well right now, its stock is expensive and could be due for a correction soon.</p>\n<h3>2. fuboTV</h3>\n<p>Streaming and entertainment company fuboTV isn't profitable, nor does profitability look to be in its sights. But that hasn't stopped investors from jumping on its bandwagon, driving shares up by more than 160% in 12 months. Its subscriber base as of March 31 topped 590,000 people -- a year-over-year increase of 105%. And the company may continue attracting more subscribers thanks to plans to launch a sportsbook before the end of the year.</p>\n<p>However, while the company is growing fast, my concern is that its approach may be <i>too </i>aggressive in pursuing revenue. In its most recent quarterly results, for the period ending March 31, revenue of $120 million was nowhere near enough to cover its $185 million in operating expenses. Of particular concern is that fuboTV has incurred subscriber-related expenses of $113 million -- more than the $107 million it brought in from subscription-related revenue.</p>\n<p>Without good margins to support the company's growth, the problem for investors is that fuboTV's financials may not get stronger as it expands, which could lead to an inevitable need to raise cash -- diluting existing shareholders. fuboTV currently trades at a multiple of 6 times its revenue, and although that's cheaper than <b><a href=\"https://laohu8.com/S/NFLX\">Netflix</a></b>'s multiple of more than 9, the streaming giant is at least profitable. In a crash, investors look for safety, and without a strong bottom line, fuboTV's stock could fall quickly.</p>\n<h3>3. Pinterest</h3>\n<p>Pinterest's stock has benefited from people staying at home during the pandemic and using its discovery engine to explore hobbies and interests. As of the end of March, the company had 478 million monthly active users (MAUs), an increase of 30% year over year. That tops last year's results, in which MAUs of 367 million grew by 26%. The company does expect to see a slowdown next quarter, however, with its MAU growth rate likely to be in the \"mid-teens.\"</p>\n<p>Even with the rising user base and a 78% year-over-year increase in sales this past quarter to $485 million, the company still posted a net loss of $22 million. Although that was a fraction of the $141 million loss it incurred a year earlier, with the economy opening back up and people going back to their regular habits, there may be less time to spend on Pinterest -- and a decline in MAUs. If that happens, the progress the company has been making on its bottom line could be stalled.</p>\n<p>Pinterest has been a hot stay-at-home stock, but now could become a risky buy given its hefty valuation; currently, the growth stock trades at more than 22 times its revenue -- the average holding in the <b><a href=\"https://laohu8.com/S/XLK\">Technology Select Sector SPDR Fund</a>&nbsp;</b>trades at a multiple of less than 7.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Expensive Stocks I'd Sell Before the Next Market Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Expensive Stocks I'd Sell Before the Next Market Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/20/3-expensive-stocks-id-sell-before-the-next-market/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market has been soaring to new heights in recent weeks and months, even though the coronavirus persists in some places, the economy hasn't fully recovered, and stimulus payments are still ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/20/3-expensive-stocks-id-sell-before-the-next-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FUBO":"fuboTV Inc.","PINS":"Pinterest, Inc.","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/20/3-expensive-stocks-id-sell-before-the-next-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152693458","content_text":"The stock market has been soaring to new heights in recent weeks and months, even though the coronavirus persists in some places, the economy hasn't fully recovered, and stimulus payments are still propping things up. All this creates a risk that as things get back to normal, the market overall could be due for a correction. Some of the money that has been flowing into it could be cashed out and put back into bonds as interest rates rise, or used for other purposes as spending resumes and people choose to hold less in stocks.\nIf I owned Moderna, Inc. , fuboTV Inc., or Pinterest, Inc., I'd be considering selling them right now. Each company's share prices has more than doubled in the past year, blowing past the S&P 500 and its 35% gains during that time. But with inflated valuations and the possibility of a crash looming, they become riskier as each day passes by.\n\nImage source: Getty Images.\n1. Moderna\nModerna has soared by 250% in 12 months, and for good reason -- its COVID-19 vaccine obtained emergency use authorization from the U.S. Food and Drug Administration (FDA) last year. The company expects to generate more than $18 billion in revenue from the vaccine in 2021, and its bottom line will finally be in the black -- in 2020 its losses totaled $747 million, triple what it lost in 2017.\nThings are certainly looking up for Moderna, especially with rival Pfizer looking to get the OK from the FDA for a third dose of its vaccine to help fight the delta variant. If Pfizer is successful, it's likely Moderna would follow suit, which could bring in even more revenue for the company. But there's no certainty that will happen. And more vaccines could be coming to market soon, including one from Novavax, which plans to apply for authorization from the FDA during the third quarter.\nAs countries have more options for vaccines, that will inevitably bring down the revenue and potential market share for Moderna. And beyond that, there are questions about what the future holds for Moderna after COVID-19. While its mRNA technology has proven to be effective, that doesn't guarantee that other vaccines in its pipeline will succeed. Its vaccine for cytomegalovirus, currently the furthest along, is entering phase 3 trials. With a peak annual revenue potential of between $2 billion and $5 billion, however, the company won't be able to solely rely on it in replacing COVID-19-related revenue.\nModerna's future is a question mark for me, and while its forward price-to-earnings ratio of 11 looks cheap, that could change drastically post-COVID. Even on a forward basis, the stock is trading at more than 6 times revenue -- Pfizer is at just 3. Although Moderna is doing well right now, its stock is expensive and could be due for a correction soon.\n2. fuboTV\nStreaming and entertainment company fuboTV isn't profitable, nor does profitability look to be in its sights. But that hasn't stopped investors from jumping on its bandwagon, driving shares up by more than 160% in 12 months. Its subscriber base as of March 31 topped 590,000 people -- a year-over-year increase of 105%. And the company may continue attracting more subscribers thanks to plans to launch a sportsbook before the end of the year.\nHowever, while the company is growing fast, my concern is that its approach may be too aggressive in pursuing revenue. In its most recent quarterly results, for the period ending March 31, revenue of $120 million was nowhere near enough to cover its $185 million in operating expenses. Of particular concern is that fuboTV has incurred subscriber-related expenses of $113 million -- more than the $107 million it brought in from subscription-related revenue.\nWithout good margins to support the company's growth, the problem for investors is that fuboTV's financials may not get stronger as it expands, which could lead to an inevitable need to raise cash -- diluting existing shareholders. fuboTV currently trades at a multiple of 6 times its revenue, and although that's cheaper than Netflix's multiple of more than 9, the streaming giant is at least profitable. In a crash, investors look for safety, and without a strong bottom line, fuboTV's stock could fall quickly.\n3. Pinterest\nPinterest's stock has benefited from people staying at home during the pandemic and using its discovery engine to explore hobbies and interests. As of the end of March, the company had 478 million monthly active users (MAUs), an increase of 30% year over year. That tops last year's results, in which MAUs of 367 million grew by 26%. The company does expect to see a slowdown next quarter, however, with its MAU growth rate likely to be in the \"mid-teens.\"\nEven with the rising user base and a 78% year-over-year increase in sales this past quarter to $485 million, the company still posted a net loss of $22 million. Although that was a fraction of the $141 million loss it incurred a year earlier, with the economy opening back up and people going back to their regular habits, there may be less time to spend on Pinterest -- and a decline in MAUs. If that happens, the progress the company has been making on its bottom line could be stalled.\nPinterest has been a hot stay-at-home stock, but now could become a risky buy given its hefty valuation; currently, the growth stock trades at more than 22 times its revenue -- the average holding in the Technology Select Sector SPDR Fund trades at a multiple of less than 7.","news_type":1},"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178113315,"gmtCreate":1626791351137,"gmtModify":1703765321851,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":19,"repostSize":0,"link":"https://ttm.financial/post/178113315","repostId":"2152405667","repostType":4,"repost":{"id":"2152405667","pubTimestamp":1626790080,"share":"https://www.laohu8.com/m/news/2152405667?lang=&edition=full","pubTime":"2021-07-20 22:08","market":"us","language":"en","title":"3 Areas Where Pfizer Is Crushing Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2152405667","media":"Motley Fool","summary":"They could result in a broader market for Pfizer's vaccine.","content":"<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> </b>and <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> have been marching in lockstep for nearly a year. They both announced the start of phase 3 trials for their coronavirus vaccine candidates on the same day last July. Pfizer won Emergency Use Authorization for its vaccine only about a week ahead of Moderna. And the U.S. ordered 300 million doses from each company earlier in the year. That was enough to vaccinate almost the entire population.</p>\n<p>It's fair to say both of these companies today are leading the coronavirus vaccine market. Still, Pfizer has inched ahead in a couple of ways. It has fully vaccinated more Americans than Moderna so far. And recently, it scored an order for as many as 1.8 billion doses from the European Union through 2023. That's in addition to an earlier order. But that's not all. There are three other areas where Pfizer is beating Moderna...</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634091%2Fgettyimages-surprised-business-person.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. The path to full approval</h3>\n<p>Pfizer and partner <b>BioNTech</b> said last week the U.S. Food and Drug Administration granted their vaccine priority review. The agency's standard review time usually takes between six to 10 months. Priority review takes a maximum of six. So, in this case, the agency's deadline to make an approval decision is in January. In even better news, an FDA official told CNN that regulators may issue a decision in as little as two months.</p>\n<p>Where does Moderna stand? The biotech submitted its request for approval a month behind Pfizer. Moderna also requested priority review. If all goes smoothly for Moderna, it may follow in Pfizer's footsteps. And in this case, we might expect a regulatory decision about a month after the Pfizer decision. If any issues arise, of course, Moderna could fall behind.</p>\n<h3>2. The booster plan</h3>\n<p>Pfizer and Moderna announced work on boosters to address variants earlier this year. Both companies are studying variant-specific candidates as well as an extra dose of their vaccines. But Pfizer made the study of a third vaccine dose the priority. And the company recently said it will ask for regulatory authorization of that dose in the coming weeks. Meanwhile, it plans to begin clinical trials of a variant-specific version of its vaccine in August.</p>\n<p>Moderna simultaneously started clinical trials of three candidates: an extra dose of vaccine, a strain-specific candidate, and a combination of its vaccine and the strain-specific candidate. The company has said it will have a booster ready by fall.</p>\n<p>If Pfizer stays on track, it looks like it will make it to market ahead of Moderna though. Pfizer's data are ready for regulators -- and it may be easier to win authorization for another dose of a vaccine that's already been given to millions of people than a new candidate.</p>\n<h3>3. Back-to-school vaccinations</h3>\n<p>Regulators in the U.S. and Europe authorized Pfizer's vaccine in teens 12 through 15 back in May. The original authorization includes individuals ages 16 and older. The company reported positive trial data on March 31.</p>\n<p>Moderna announced positive results from its teen study in late May -- and the company applied for authorization in the U.S. and Europe about two weeks later. Regulatory decisions may come any day now. But Pfizer has a clear advantage. Its vaccine got the OK before teens headed off to summer activities or vacation. And that's likely when a lot of teens would opt for vaccination to be fully protected before school starts. Pfizer and Moderna vaccines require two doses about a month apart.</p>\n<h3>What does all of this mean for investors?</h3>\n<p>These points are good news for Pfizer. A fully approved vaccine likely will attract many individuals who hesitated to go for an experimental product. So, if the FDA gives a nod, more and more people may request a Pfizer jab. A quicker-to-market booster and an authorization for teens also mean more individuals may go for a Pfizer shot in the near term.</p>\n<p>But none of these points will immediately equal more revenue for Pfizer. Governments already have purchased doses. If Pfizer <i>stays </i>ahead of Moderna on each of the above points, though, these doses may be used up faster than planned. And that may mean more orders down the road. And therefore, more revenue. The first-to-market status also may keep governments coming back for more of the same -- so Pfizer may attract bigger orders.</p>\n<p>All is not lost for Moderna though. Far from it. Yes, Pfizer is dominating in the above areas. And that may even continue. But Moderna isn't far behind. As we've seen so far, there's room for more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> player in this market. Pfizer expects $26 billion in vaccine revenue this year. And Moderna's advance purchase orders total $19.2 billion so far. Both already are winning orders for 2022.</p>\n<p>This means an investment in either of these coronavirus vaccine leaders today is likely to pay off now -- and in the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Areas Where Pfizer Is Crushing Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Areas Where Pfizer Is Crushing Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 22:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/20/3-areas-where-pfizer-is-crushing-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer and Moderna, Inc. have been marching in lockstep for nearly a year. They both announced the start of phase 3 trials for their coronavirus vaccine candidates on the same day last July. Pfizer ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/20/3-areas-where-pfizer-is-crushing-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/20/3-areas-where-pfizer-is-crushing-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152405667","content_text":"Pfizer and Moderna, Inc. have been marching in lockstep for nearly a year. They both announced the start of phase 3 trials for their coronavirus vaccine candidates on the same day last July. Pfizer won Emergency Use Authorization for its vaccine only about a week ahead of Moderna. And the U.S. ordered 300 million doses from each company earlier in the year. That was enough to vaccinate almost the entire population.\nIt's fair to say both of these companies today are leading the coronavirus vaccine market. Still, Pfizer has inched ahead in a couple of ways. It has fully vaccinated more Americans than Moderna so far. And recently, it scored an order for as many as 1.8 billion doses from the European Union through 2023. That's in addition to an earlier order. But that's not all. There are three other areas where Pfizer is beating Moderna...\n\nImage source: Getty Images.\n1. The path to full approval\nPfizer and partner BioNTech said last week the U.S. Food and Drug Administration granted their vaccine priority review. The agency's standard review time usually takes between six to 10 months. Priority review takes a maximum of six. So, in this case, the agency's deadline to make an approval decision is in January. In even better news, an FDA official told CNN that regulators may issue a decision in as little as two months.\nWhere does Moderna stand? The biotech submitted its request for approval a month behind Pfizer. Moderna also requested priority review. If all goes smoothly for Moderna, it may follow in Pfizer's footsteps. And in this case, we might expect a regulatory decision about a month after the Pfizer decision. If any issues arise, of course, Moderna could fall behind.\n2. The booster plan\nPfizer and Moderna announced work on boosters to address variants earlier this year. Both companies are studying variant-specific candidates as well as an extra dose of their vaccines. But Pfizer made the study of a third vaccine dose the priority. And the company recently said it will ask for regulatory authorization of that dose in the coming weeks. Meanwhile, it plans to begin clinical trials of a variant-specific version of its vaccine in August.\nModerna simultaneously started clinical trials of three candidates: an extra dose of vaccine, a strain-specific candidate, and a combination of its vaccine and the strain-specific candidate. The company has said it will have a booster ready by fall.\nIf Pfizer stays on track, it looks like it will make it to market ahead of Moderna though. Pfizer's data are ready for regulators -- and it may be easier to win authorization for another dose of a vaccine that's already been given to millions of people than a new candidate.\n3. Back-to-school vaccinations\nRegulators in the U.S. and Europe authorized Pfizer's vaccine in teens 12 through 15 back in May. The original authorization includes individuals ages 16 and older. The company reported positive trial data on March 31.\nModerna announced positive results from its teen study in late May -- and the company applied for authorization in the U.S. and Europe about two weeks later. Regulatory decisions may come any day now. But Pfizer has a clear advantage. Its vaccine got the OK before teens headed off to summer activities or vacation. And that's likely when a lot of teens would opt for vaccination to be fully protected before school starts. Pfizer and Moderna vaccines require two doses about a month apart.\nWhat does all of this mean for investors?\nThese points are good news for Pfizer. A fully approved vaccine likely will attract many individuals who hesitated to go for an experimental product. So, if the FDA gives a nod, more and more people may request a Pfizer jab. A quicker-to-market booster and an authorization for teens also mean more individuals may go for a Pfizer shot in the near term.\nBut none of these points will immediately equal more revenue for Pfizer. Governments already have purchased doses. If Pfizer stays ahead of Moderna on each of the above points, though, these doses may be used up faster than planned. And that may mean more orders down the road. And therefore, more revenue. The first-to-market status also may keep governments coming back for more of the same -- so Pfizer may attract bigger orders.\nAll is not lost for Moderna though. Far from it. Yes, Pfizer is dominating in the above areas. And that may even continue. But Moderna isn't far behind. As we've seen so far, there's room for more than one player in this market. Pfizer expects $26 billion in vaccine revenue this year. And Moderna's advance purchase orders total $19.2 billion so far. Both already are winning orders for 2022.\nThis means an investment in either of these coronavirus vaccine leaders today is likely to pay off now -- and in the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171914302,"gmtCreate":1626702285606,"gmtModify":1703763622610,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":18,"repostSize":0,"link":"https://ttm.financial/post/171914302","repostId":"1146536243","repostType":4,"repost":{"id":"1146536243","pubTimestamp":1626683272,"share":"https://www.laohu8.com/m/news/1146536243?lang=&edition=full","pubTime":"2021-07-19 16:27","market":"us","language":"en","title":"Morgan Stanley: This Cycle Will Be \"Hotter But Shorter\" Than Usual","url":"https://stock-news.laohu8.com/highlight/detail?id=1146536243","media":"zerohedge","summary":"This cycle is unusual. Most 'normal' cycles are. We think that the recovery is sustainable and more likely to be ‘hotter and shorter’. Sell Treasuries and trust the expansion.","content":"<p>We think that this economic cycle will be normal, strong and short. Each of these assumptions is being hotly debated by the market. Each is key to our investment strategy.</p>\n<p>The debate over cycle 'normalcy' is self-explanatory. The pandemic created, without exaggeration, the single sharpest decline in output in recorded history. Then activity raced back, helped by policy support. The case for viewing this situation as unique, and distinct from other cyclical experiences, is based on the view that a fall and rise this violent never allowed for a traditional 'reset'.</p>\n<p>But 'normal' in markets is a funny concept, with the rough edges of memory often smoothed and polished by the passage of time. The cycle of 2003-07 ended with the largest banking and housing crisis since the Great Depression. The cycle of 1992-2000 ended with the bursting of an enormous equity bubble, widespread accounting fraud and unspeakable tragedy. 'Normal' cycles are nice in theory, harder in practice.</p>\n<p>Instead, let’s consider why we use the term ‘cycle’ at all. Economies and markets tend to follow cyclical patterns, patterns that tend to show up in market performance. It is those patterns we care about, and if they still apply, they can provide a useful guide in uncertain terrain.</p>\n<p>Was last year’s recession preceded by late-cycle conditions such as an inverted yield curve, low volatility, low unemployment, high consumer confidence and narrowing equity market breadth? It was. Did the resulting troughs in equities, credit, yields and yield curves match the usual cadence between market and economic lows? They did. And were the leaders of the ensuing rally the usual early-cycle winners, like small and cyclical stocks, high yield credit and industrial metals? They were.</p>\n<p>If it walks like a duck and quacks like a duck, we think that it’s a normal cycle. Or as normal as these things realistically are.&nbsp;If a lot of 'normal' cycle behavior has played out so far, it should&nbsp;<i>continue</i>&nbsp;to do so.</p>\n<p>Specifically, this relates to patterns of performance as the market recovers. And as that recovery advances, those patterns should shift. As noted by my colleague Michael Wilson, we think that we are moving to a mid-cycle market, despite being just 16 months removed from the lows of economic activity. We see a number of similarities between current conditions and 1H04, a mid-cycle period that followed a large, reflationary rally. And importantly, despite recent fears about growth, we think that the global recovery will keep pushing on (see&nbsp;The Growth Scare Anniversary, July 11, 2021).</p>\n<p>Because one can always find an indicator that fits their particular cycle view, we’ve long been fans of a composite. That’s our ‘cycle model’, which combines ten US metrics across macro, the credit cycle and corporate aggression to gauge where we are in the market cycle. After moving into late-cycle ‘downturn’ in June 2019, and early-cycle ‘repair’ in April 2020, it’s rocketed higher.<b>It has risen so fast that it’s blown right past what should be the next phase ('recovery'), and moved right into ‘expansion’.</b></p>\n<p><img src=\"https://static.tigerbbs.com/41879c4f66b33597ee236bdd52841004\" tg-width=\"904\" tg-height=\"490\" referrerpolicy=\"no-referrer\">Thisis unusual. ‘Expansion’ is meant to capture conditions that are 'better than normal, and improving',<b>and since 1980, it has taken an average of 35 months to get there after 'downturn' ends</b>. Its speedy arrival speaks to a speedy recovery powered by enormous policy support.<b>It also hints at another possibility:&nbsp;this hotter cycle could be shorter.</b>This is our thesis, and it’s showing up in our quantitative measure.</p>\n<p>All this has a number of implications:</p>\n<ul>\n <li><b>The shorter the cycle, the worse for credit relative to other risky assets; credit enjoys fewer of the gains from the 'boom', is exposed if the next downturn is early, and faces more supply as corporate confidence increases</b>. In the ‘expansion’ phase of our cycle model, US IG and HY credit N12M excess returns are 29bp and 161bp worse than average, respectively.</li>\n <li><b>In many of those periods, more mixed credit performance occurs despite default rates remaining low</b>. Investors should try to take default risk over spread risk: our credit strategists like owning CDX HY 0-15%, and hedging with CDX IG payer spreads.</li>\n <li><b>In equities, we think that our model supports more balance in portfolios</b>. We like healthcare in both the US and Europe as a sector with several nice factor exposures: quality, low valuation, high carry and low volatility. Globally, equities in Europe and Japan have tended to outperform 'mid-cycle', and we think that they can do so again.</li>\n <li><b>Interest rates are too pessimistic on the recovery. US 10-year Treasury N12M returns are 97bp worse than average during the ‘expansion’ phase of our cycle model</b>. Guneet Dhingra and our US interest rate strategy team have moved underweight US 10-year Treasuries, and we in turn have moved back underweight government bonds in our global asset allocation.</li>\n</ul>\n<p>This cycle is unusual. Most 'normal' cycles are. We think that the recovery is sustainable and more likely to be ‘hotter and shorter’. Sell Treasuries and trust the expansion.</p>","source":"lsy1583725640930","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: This Cycle Will Be \"Hotter But Shorter\" Than Usual</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: This Cycle Will Be \"Hotter But Shorter\" Than Usual\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-19 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/morgan-stanley-cycle-will-be-hotter-shorter-usual><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We think that this economic cycle will be normal, strong and short. Each of these assumptions is being hotly debated by the market. Each is key to our investment strategy.\nThe debate over cycle '...</p>\n\n<a href=\"https://www.zerohedge.com/markets/morgan-stanley-cycle-will-be-hotter-shorter-usual\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.zerohedge.com/markets/morgan-stanley-cycle-will-be-hotter-shorter-usual","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146536243","content_text":"We think that this economic cycle will be normal, strong and short. Each of these assumptions is being hotly debated by the market. Each is key to our investment strategy.\nThe debate over cycle 'normalcy' is self-explanatory. The pandemic created, without exaggeration, the single sharpest decline in output in recorded history. Then activity raced back, helped by policy support. The case for viewing this situation as unique, and distinct from other cyclical experiences, is based on the view that a fall and rise this violent never allowed for a traditional 'reset'.\nBut 'normal' in markets is a funny concept, with the rough edges of memory often smoothed and polished by the passage of time. The cycle of 2003-07 ended with the largest banking and housing crisis since the Great Depression. The cycle of 1992-2000 ended with the bursting of an enormous equity bubble, widespread accounting fraud and unspeakable tragedy. 'Normal' cycles are nice in theory, harder in practice.\nInstead, let’s consider why we use the term ‘cycle’ at all. Economies and markets tend to follow cyclical patterns, patterns that tend to show up in market performance. It is those patterns we care about, and if they still apply, they can provide a useful guide in uncertain terrain.\nWas last year’s recession preceded by late-cycle conditions such as an inverted yield curve, low volatility, low unemployment, high consumer confidence and narrowing equity market breadth? It was. Did the resulting troughs in equities, credit, yields and yield curves match the usual cadence between market and economic lows? They did. And were the leaders of the ensuing rally the usual early-cycle winners, like small and cyclical stocks, high yield credit and industrial metals? They were.\nIf it walks like a duck and quacks like a duck, we think that it’s a normal cycle. Or as normal as these things realistically are. If a lot of 'normal' cycle behavior has played out so far, it should continue to do so.\nSpecifically, this relates to patterns of performance as the market recovers. And as that recovery advances, those patterns should shift. As noted by my colleague Michael Wilson, we think that we are moving to a mid-cycle market, despite being just 16 months removed from the lows of economic activity. We see a number of similarities between current conditions and 1H04, a mid-cycle period that followed a large, reflationary rally. And importantly, despite recent fears about growth, we think that the global recovery will keep pushing on (see The Growth Scare Anniversary, July 11, 2021).\nBecause one can always find an indicator that fits their particular cycle view, we’ve long been fans of a composite. That’s our ‘cycle model’, which combines ten US metrics across macro, the credit cycle and corporate aggression to gauge where we are in the market cycle. After moving into late-cycle ‘downturn’ in June 2019, and early-cycle ‘repair’ in April 2020, it’s rocketed higher.It has risen so fast that it’s blown right past what should be the next phase ('recovery'), and moved right into ‘expansion’.\nThisis unusual. ‘Expansion’ is meant to capture conditions that are 'better than normal, and improving',and since 1980, it has taken an average of 35 months to get there after 'downturn' ends. Its speedy arrival speaks to a speedy recovery powered by enormous policy support.It also hints at another possibility: this hotter cycle could be shorter.This is our thesis, and it’s showing up in our quantitative measure.\nAll this has a number of implications:\n\nThe shorter the cycle, the worse for credit relative to other risky assets; credit enjoys fewer of the gains from the 'boom', is exposed if the next downturn is early, and faces more supply as corporate confidence increases. In the ‘expansion’ phase of our cycle model, US IG and HY credit N12M excess returns are 29bp and 161bp worse than average, respectively.\nIn many of those periods, more mixed credit performance occurs despite default rates remaining low. Investors should try to take default risk over spread risk: our credit strategists like owning CDX HY 0-15%, and hedging with CDX IG payer spreads.\nIn equities, we think that our model supports more balance in portfolios. We like healthcare in both the US and Europe as a sector with several nice factor exposures: quality, low valuation, high carry and low volatility. Globally, equities in Europe and Japan have tended to outperform 'mid-cycle', and we think that they can do so again.\nInterest rates are too pessimistic on the recovery. US 10-year Treasury N12M returns are 97bp worse than average during the ‘expansion’ phase of our cycle model. Guneet Dhingra and our US interest rate strategy team have moved underweight US 10-year Treasuries, and we in turn have moved back underweight government bonds in our global asset allocation.\n\nThis cycle is unusual. Most 'normal' cycles are. We think that the recovery is sustainable and more likely to be ‘hotter and shorter’. Sell Treasuries and trust the expansion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173356866,"gmtCreate":1626621020855,"gmtModify":1703762404343,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/173356866","repostId":"1183956332","repostType":4,"repost":{"id":"1183956332","pubTimestamp":1626568120,"share":"https://www.laohu8.com/m/news/1183956332?lang=&edition=full","pubTime":"2021-07-18 08:28","market":"us","language":"en","title":"US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1183956332","media":"renaissancecap...","summary":"The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.The largest deal of the week, specialty insurance brokerage Ryan Specialty Group plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in t","content":"<p>The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.</p>\n<p>The largest deal of the week, specialty insurance brokerage&nbsp;<b>Ryan Specialty Group</b>(RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in the 1Q21, the company will be leveraged post-IPO.</p>\n<p>Water infrastructure company&nbsp;<b>Core &amp; Main</b>(CNM) plans to raise $750 million at a $5.2 billion market cap in a 100% synthetic secondary offering. Profitable with solid growth, the company distributes water infrastructure products that connect 4,500 suppliers to over 60,000 municipal, non-residential, and residential customers.</p>\n<p>HR software provider&nbsp;<b>Paycor HCM</b>(PYCR) plans to raise $361 million at a $3.4 billion market cap. Paycor provides human capital management software to small and mid-sized businesses, covering the payroll process and key HR functionality. While net revenue retention fell in the FY20, the company is targeting a large addressable market and has a track record of profitability.</p>\n<p>Latin <a href=\"https://laohu8.com/S/AFG\">American</a> e-commerce platform&nbsp;<b><a href=\"https://laohu8.com/S/VTEX\">VTEX</a></b>(VTEX) plans to raise $304 million at a $3.2 billion market cap. VTEX operates a business-to-consumer e-commerce platform to enterprise customers that natively combines commerce, order management, and marketplace functionality. The company has demonstrated growth, though investments in SG&amp;A and R&amp;D have weighed on profits.</p>\n<p>Learning management platform&nbsp;<b>Instructure Holdings</b>(INST) plans to raise $250 million at a $2.9 billion market cap. The company provides a next-generation Learning Management System (LMS), assessments for learning, actionable analytics, and dynamic content. Instructure states that it is the LMS market leader in both Higher Education and paid K-12, with over 6,000 global customers across 90 countries.</p>\n<p>Protein discovery and development platform&nbsp;<b>AbSci</b>(ABSI) plans to raise $200 million at a $1.6 billion market cap. AbSci currently has nine active programs across seven partners, which include <a href=\"https://laohu8.com/S/MRK\">Merck</a> and Astellas, for which it has either negotiated or plans to negotiate license agreements. The company is highly unprofitable, and 90% of its tech development revenue came from a single partner in the 1Q21.</p>\n<p>Organic beverage brand&nbsp;<b><a href=\"https://laohu8.com/S/ZVIA\">Zevia PBC</a></b>(ZVIA) plans to raise $200 million at a $1.0 billion market cap. Zevia provides six product lines of zero calorie, zero sugar, naturally sweetened beverages in the US and Canada. The company has demonstrated growth and achieved profitability in the 1Q21.</p>\n<p>Content marketing platform&nbsp;<b>Outbrain</b>(OB) plans to raise $200 million at a $1.5 billion market cap. Outbrain’s platform enables over 7,000 online properties, helping them engage their users and monetize their visits by gathering over 1 billion data events each minute. Profitable with strong growth, the company had over 20,000 advertisers using its platform in 2020.</p>\n<p>Fitness franchisor&nbsp;<b>Xponential Fitness</b>(XPOF) plans to raise $200 million at a $711 million market cap. Xponential Fitness is the largest boutique fitness franchisor in the US with over 1,750 studios operating across nine distinct brands. While the company’s business was impacted by the pandemic in 2020, preliminary results for the 2Q21 show 60%+ revenue growth and adjusted EBITDA swinging positive.</p>\n<p>Legal software provider&nbsp;<b>CS Disco</b>(LAW) plans to raise $193 million at a $1.6 billion market cap. Fast growing and unprofitable, DISCO provides a cloud-native, AI-powered legal solution that simplifies ediscovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments.</p>\n<p>Following its postponement in May, Brazil’s&nbsp;<b>Zenvia</b>(ZENV) plans to raise $162 million at a $548 million market cap. The company’s software platform facilitated the flow of communication for more than 10,190 customers throughout Latin America as of March 31, 2021. While it achieved a net revenue expansion rate of nearly 110%, Zenvia’s EBITDA turned negative in the 1Q21.</p>\n<p><b>Couchbase</b>(BASE) plans to raise $151 million at a $992 million market cap. Couchbase provides a NoSQL database that enables enterprises and developers to build and run applications across the cloud, on-premise, hybrid, or mobile and edge environments. The company has a sticky customer base that includes 30% of the Fortune 100, though it remains unprofitable due to high S&amp;M costs.</p>\n<p>Following its postponement in April,<b>Kaltura</b>(KLTR) plans to raise $150 million at a $1.4 billion market cap. Kaltura provides live, real-time, and on-demand video products to a wide range of businesses including educational institutions, and media and telecom companies. Thanks to the growing adoption of virtual events, the company saw revenue expand in the 1Q21, though gross margin contracted.</p>\n<p><b>Gambling.com Group</b>(GAMB) plans to raise $90 million at a $435 million market cap. Gambling.com Group is a performance marketing company and a digital marketing services provider active exclusively in the online gambling industry, with a principal focus on iGaming and sports betting. Profitable and fast growing, the company has increased its customer base from 131 in 2017 to over 200 in 2020.</p>\n<p>Three biotechs are expected to round out the week: cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL), which plans to raise $85 million at a $398 million market cap; preclinical biotech&nbsp;<b>Ocean Biomedical</b>(OCEA), which plans to raise $50 million at a $506 million market cap; and cancer biotech&nbsp;<b>Elicio Therapeutics</b>(ELTX), which plans to raise $40 million at a $201 million market cap.</p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-18 08:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.\nThe largest deal of the week, specialty insurance brokerage Ryan ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CNM":"Core & Main, Inc.","OB":"Outbrain Inc.","INST":"Instructure Holdings, Inc.","PYCR":"Paycor HCM, Inc.","GAMB":"Gambling.com Group Limited","CADL":"Candel Therapeutics, Inc.","LAW":"CS Disco, Inc.","BASE":"Couchbase, Inc.","ZVIA":"Zevia PBC","OCEA":"Ocean Biomedical","VTEX":"VTEX","ABSI":"Absci Corporation.","RYAN":"Ryan Specialty Group Holdings, Inc.","ELTX":"Elicio Therapeutics"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183956332","content_text":"The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.\nThe largest deal of the week, specialty insurance brokerage Ryan Specialty Group(RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in the 1Q21, the company will be leveraged post-IPO.\nWater infrastructure company Core & Main(CNM) plans to raise $750 million at a $5.2 billion market cap in a 100% synthetic secondary offering. Profitable with solid growth, the company distributes water infrastructure products that connect 4,500 suppliers to over 60,000 municipal, non-residential, and residential customers.\nHR software provider Paycor HCM(PYCR) plans to raise $361 million at a $3.4 billion market cap. Paycor provides human capital management software to small and mid-sized businesses, covering the payroll process and key HR functionality. While net revenue retention fell in the FY20, the company is targeting a large addressable market and has a track record of profitability.\nLatin American e-commerce platform VTEX(VTEX) plans to raise $304 million at a $3.2 billion market cap. VTEX operates a business-to-consumer e-commerce platform to enterprise customers that natively combines commerce, order management, and marketplace functionality. The company has demonstrated growth, though investments in SG&A and R&D have weighed on profits.\nLearning management platform Instructure Holdings(INST) plans to raise $250 million at a $2.9 billion market cap. The company provides a next-generation Learning Management System (LMS), assessments for learning, actionable analytics, and dynamic content. Instructure states that it is the LMS market leader in both Higher Education and paid K-12, with over 6,000 global customers across 90 countries.\nProtein discovery and development platform AbSci(ABSI) plans to raise $200 million at a $1.6 billion market cap. AbSci currently has nine active programs across seven partners, which include Merck and Astellas, for which it has either negotiated or plans to negotiate license agreements. The company is highly unprofitable, and 90% of its tech development revenue came from a single partner in the 1Q21.\nOrganic beverage brand Zevia PBC(ZVIA) plans to raise $200 million at a $1.0 billion market cap. Zevia provides six product lines of zero calorie, zero sugar, naturally sweetened beverages in the US and Canada. The company has demonstrated growth and achieved profitability in the 1Q21.\nContent marketing platform Outbrain(OB) plans to raise $200 million at a $1.5 billion market cap. Outbrain’s platform enables over 7,000 online properties, helping them engage their users and monetize their visits by gathering over 1 billion data events each minute. Profitable with strong growth, the company had over 20,000 advertisers using its platform in 2020.\nFitness franchisor Xponential Fitness(XPOF) plans to raise $200 million at a $711 million market cap. Xponential Fitness is the largest boutique fitness franchisor in the US with over 1,750 studios operating across nine distinct brands. While the company’s business was impacted by the pandemic in 2020, preliminary results for the 2Q21 show 60%+ revenue growth and adjusted EBITDA swinging positive.\nLegal software provider CS Disco(LAW) plans to raise $193 million at a $1.6 billion market cap. Fast growing and unprofitable, DISCO provides a cloud-native, AI-powered legal solution that simplifies ediscovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments.\nFollowing its postponement in May, Brazil’s Zenvia(ZENV) plans to raise $162 million at a $548 million market cap. The company’s software platform facilitated the flow of communication for more than 10,190 customers throughout Latin America as of March 31, 2021. While it achieved a net revenue expansion rate of nearly 110%, Zenvia’s EBITDA turned negative in the 1Q21.\nCouchbase(BASE) plans to raise $151 million at a $992 million market cap. Couchbase provides a NoSQL database that enables enterprises and developers to build and run applications across the cloud, on-premise, hybrid, or mobile and edge environments. The company has a sticky customer base that includes 30% of the Fortune 100, though it remains unprofitable due to high S&M costs.\nFollowing its postponement in April,Kaltura(KLTR) plans to raise $150 million at a $1.4 billion market cap. Kaltura provides live, real-time, and on-demand video products to a wide range of businesses including educational institutions, and media and telecom companies. Thanks to the growing adoption of virtual events, the company saw revenue expand in the 1Q21, though gross margin contracted.\nGambling.com Group(GAMB) plans to raise $90 million at a $435 million market cap. Gambling.com Group is a performance marketing company and a digital marketing services provider active exclusively in the online gambling industry, with a principal focus on iGaming and sports betting. Profitable and fast growing, the company has increased its customer base from 131 in 2017 to over 200 in 2020.\nThree biotechs are expected to round out the week: cancer biotech Candel Therapeutics(CADL), which plans to raise $85 million at a $398 million market cap; preclinical biotech Ocean Biomedical(OCEA), which plans to raise $50 million at a $506 million market cap; and cancer biotech Elicio Therapeutics(ELTX), which plans to raise $40 million at a $201 million market cap.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":809890840,"gmtCreate":1627355930980,"gmtModify":1703488271587,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":33,"repostSize":1,"link":"https://ttm.financial/post/809890840","repostId":"2154964378","repostType":4,"isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172899134,"gmtCreate":1626948477928,"gmtModify":1703481142037,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":22,"repostSize":0,"link":"https://ttm.financial/post/172899134","repostId":"1149385054","repostType":4,"repost":{"id":"1149385054","pubTimestamp":1626945470,"share":"https://www.laohu8.com/m/news/1149385054?lang=&edition=full","pubTime":"2021-07-22 17:17","market":"us","language":"en","title":"Why Nvidia Stock Jumped Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1149385054","media":"Motley Fool","summary":"After a short pullback following Nvidia's recent stock split, investors went right back to bidding u","content":"<blockquote>\n After a short pullback following Nvidia's recent stock split, investors went right back to bidding up the tech titan's shares.\n</blockquote>\n<p><b>What happened</b></p>\n<p><b><a href=\"https://laohu8.com/S/NVDA\">NVIDIA Corp</a></b> climbed 4.3% on Wednesday, following its 4-for-1 stock split on Tuesday.</p>\n<p><b>So what</b></p>\n<p>Stock splitsdon't change the fundamental value of a business. A 4-for-1 split is in many ways like exchanging a $1 bill for four quarters. The total value is the same; it's just divided into more pieces.</p>\n<p>Nevertheless, traders do tend to get excited about stock splits, and this can positively impact a stock's price leading up to the split. After the split occurs, however, traders often take the opportunity to book short-term profits. And many investors, who are now in possession of more shares, use it as a chance to sell part of their holdings and book some long-term profits.</p>\n<p>These short-term price dynamics appeared to impact Nvidia's stock in recent weeks. Its share price rose 25% from when it announced its stock split on May 21 until July 19. And after the split took place on July 20, Nvidia's shares fell as much as 3.5% before ending the day down about 1%.</p>\n<p><b>Now what</b></p>\n<p>Now that the split has occurred, investors appear to be focusing on Nvidia's fundamental growth drivers once again. And in this regard, Nvidia's future appears bright. Rising demand for its chips in booming markets, such as data centers and gaming, are driving sharp increases in revenue and profits. With this likely to remain the case for the foreseeable future, Wednesday's gains could be just part of a far larger upward move for Nvidia's share price in the coming years.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Nvidia Stock Jumped Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Nvidia Stock Jumped Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 17:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/why-nvidia-stock-jumped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a short pullback following Nvidia's recent stock split, investors went right back to bidding up the tech titan's shares.\n\nWhat happened\nNVIDIA Corp climbed 4.3% on Wednesday, following its 4-for...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/why-nvidia-stock-jumped-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/07/21/why-nvidia-stock-jumped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149385054","content_text":"After a short pullback following Nvidia's recent stock split, investors went right back to bidding up the tech titan's shares.\n\nWhat happened\nNVIDIA Corp climbed 4.3% on Wednesday, following its 4-for-1 stock split on Tuesday.\nSo what\nStock splitsdon't change the fundamental value of a business. A 4-for-1 split is in many ways like exchanging a $1 bill for four quarters. The total value is the same; it's just divided into more pieces.\nNevertheless, traders do tend to get excited about stock splits, and this can positively impact a stock's price leading up to the split. After the split occurs, however, traders often take the opportunity to book short-term profits. And many investors, who are now in possession of more shares, use it as a chance to sell part of their holdings and book some long-term profits.\nThese short-term price dynamics appeared to impact Nvidia's stock in recent weeks. Its share price rose 25% from when it announced its stock split on May 21 until July 19. And after the split took place on July 20, Nvidia's shares fell as much as 3.5% before ending the day down about 1%.\nNow what\nNow that the split has occurred, investors appear to be focusing on Nvidia's fundamental growth drivers once again. And in this regard, Nvidia's future appears bright. Rising demand for its chips in booming markets, such as data centers and gaming, are driving sharp increases in revenue and profits. With this likely to remain the case for the foreseeable future, Wednesday's gains could be just part of a far larger upward move for Nvidia's share price in the coming years.","news_type":1},"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801068405,"gmtCreate":1627474294307,"gmtModify":1703490627200,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":22,"repostSize":0,"link":"https://ttm.financial/post/801068405","repostId":"1141827079","repostType":4,"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171914302,"gmtCreate":1626702285606,"gmtModify":1703763622610,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":18,"repostSize":0,"link":"https://ttm.financial/post/171914302","repostId":"1146536243","repostType":4,"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178113315,"gmtCreate":1626791351137,"gmtModify":1703765321851,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":19,"repostSize":0,"link":"https://ttm.financial/post/178113315","repostId":"2152405667","repostType":4,"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888919421,"gmtCreate":1631420777963,"gmtModify":1676530545503,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ohhh","listText":"Ohhh","text":"Ohhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":17,"repostSize":0,"link":"https://ttm.financial/post/888919421","repostId":"809890840","repostType":1,"repost":{"id":809890840,"gmtCreate":1627355930980,"gmtModify":1703488271587,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809890840","repostId":"2154964378","repostType":4,"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178116172,"gmtCreate":1626791499196,"gmtModify":1703765323314,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I see....","listText":"I see....","text":"I see....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":15,"repostSize":0,"link":"https://ttm.financial/post/178116172","repostId":"2152693458","repostType":4,"repost":{"id":"2152693458","pubTimestamp":1626790560,"share":"https://www.laohu8.com/m/news/2152693458?lang=&edition=full","pubTime":"2021-07-20 22:16","market":"us","language":"en","title":"3 Expensive Stocks I'd Sell Before the Next Market Crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2152693458","media":"Motley Fool","summary":"Even if you love these stocks, it may not be a bad move to cash out right now.","content":"<p>The stock market has been soaring to new heights in recent weeks and months, even though the coronavirus persists in some places, the economy hasn't fully recovered, and stimulus payments are still propping things up. All this creates a risk that as things get back to normal, the market overall could be due for a correction. Some of the money that has been flowing into it could be cashed out and put back into bonds as interest rates rise, or used for other purposes as spending resumes and people choose to hold less in stocks.</p>\n<p>If I owned <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna, Inc.</a></b> , <b><a href=\"https://laohu8.com/S/FUBO\">fuboTV Inc.</a></b>, or <b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b>, I'd be considering selling them right now. Each company's share prices has more than doubled in the past year, blowing past the <b>S&amp;P 500</b> and its 35% gains during that time. But with inflated valuations and the possibility of a crash looming, they become riskier as each day passes by.</p>\n<p><img src=\"https://static.tigerbbs.com/f1da2df5b21cc39ab7b17f7b776e5045\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. Moderna</h3>\n<p>Moderna has soared by 250% in 12 months, and for good reason -- its COVID-19 vaccine obtained emergency use authorization from the U.S. Food and Drug Administration (FDA) last year. The company expects to generate more than $18 billion in revenue from the vaccine in 2021, and its bottom line will finally be in the black -- in 2020 its losses totaled $747 million, triple what it lost in 2017.</p>\n<p>Things are certainly looking up for Moderna, especially with rival&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> looking to get the OK from the FDA for a third dose of its vaccine to help fight the delta variant. If Pfizer is successful, it's likely Moderna would follow suit, which could bring in even more revenue for the company. But there's no certainty that will happen. And more vaccines could be coming to market soon, including <a href=\"https://laohu8.com/S/AONE.U\">one</a> from <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>, which plans to apply for authorization from the FDA during the third quarter.</p>\n<p>As countries have more options for vaccines, that will inevitably bring down the revenue and potential market share for Moderna. And beyond that, there are questions about what the future holds for Moderna after COVID-19. While its mRNA technology has proven to be effective, that doesn't guarantee that other vaccines in its pipeline will succeed. Its vaccine for cytomegalovirus, currently the furthest along, is entering phase 3 trials. With a peak annual revenue potential of between $2 billion and $5 billion, however, the company won't be able to solely rely on it in replacing COVID-19-related revenue.</p>\n<p>Moderna's future is a question mark for me, and while its forward price-to-earnings ratio of 11 looks cheap, that could change drastically post-COVID. Even on a forward basis, the stock is trading at more than 6 times revenue -- Pfizer is at just 3. Although Moderna is doing well right now, its stock is expensive and could be due for a correction soon.</p>\n<h3>2. fuboTV</h3>\n<p>Streaming and entertainment company fuboTV isn't profitable, nor does profitability look to be in its sights. But that hasn't stopped investors from jumping on its bandwagon, driving shares up by more than 160% in 12 months. Its subscriber base as of March 31 topped 590,000 people -- a year-over-year increase of 105%. And the company may continue attracting more subscribers thanks to plans to launch a sportsbook before the end of the year.</p>\n<p>However, while the company is growing fast, my concern is that its approach may be <i>too </i>aggressive in pursuing revenue. In its most recent quarterly results, for the period ending March 31, revenue of $120 million was nowhere near enough to cover its $185 million in operating expenses. Of particular concern is that fuboTV has incurred subscriber-related expenses of $113 million -- more than the $107 million it brought in from subscription-related revenue.</p>\n<p>Without good margins to support the company's growth, the problem for investors is that fuboTV's financials may not get stronger as it expands, which could lead to an inevitable need to raise cash -- diluting existing shareholders. fuboTV currently trades at a multiple of 6 times its revenue, and although that's cheaper than <b><a href=\"https://laohu8.com/S/NFLX\">Netflix</a></b>'s multiple of more than 9, the streaming giant is at least profitable. In a crash, investors look for safety, and without a strong bottom line, fuboTV's stock could fall quickly.</p>\n<h3>3. Pinterest</h3>\n<p>Pinterest's stock has benefited from people staying at home during the pandemic and using its discovery engine to explore hobbies and interests. As of the end of March, the company had 478 million monthly active users (MAUs), an increase of 30% year over year. That tops last year's results, in which MAUs of 367 million grew by 26%. The company does expect to see a slowdown next quarter, however, with its MAU growth rate likely to be in the \"mid-teens.\"</p>\n<p>Even with the rising user base and a 78% year-over-year increase in sales this past quarter to $485 million, the company still posted a net loss of $22 million. Although that was a fraction of the $141 million loss it incurred a year earlier, with the economy opening back up and people going back to their regular habits, there may be less time to spend on Pinterest -- and a decline in MAUs. If that happens, the progress the company has been making on its bottom line could be stalled.</p>\n<p>Pinterest has been a hot stay-at-home stock, but now could become a risky buy given its hefty valuation; currently, the growth stock trades at more than 22 times its revenue -- the average holding in the <b><a href=\"https://laohu8.com/S/XLK\">Technology Select Sector SPDR Fund</a>&nbsp;</b>trades at a multiple of less than 7.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Expensive Stocks I'd Sell Before the Next Market Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Expensive Stocks I'd Sell Before the Next Market Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/20/3-expensive-stocks-id-sell-before-the-next-market/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market has been soaring to new heights in recent weeks and months, even though the coronavirus persists in some places, the economy hasn't fully recovered, and stimulus payments are still ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/20/3-expensive-stocks-id-sell-before-the-next-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FUBO":"fuboTV Inc.","PINS":"Pinterest, Inc.","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/20/3-expensive-stocks-id-sell-before-the-next-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152693458","content_text":"The stock market has been soaring to new heights in recent weeks and months, even though the coronavirus persists in some places, the economy hasn't fully recovered, and stimulus payments are still propping things up. All this creates a risk that as things get back to normal, the market overall could be due for a correction. Some of the money that has been flowing into it could be cashed out and put back into bonds as interest rates rise, or used for other purposes as spending resumes and people choose to hold less in stocks.\nIf I owned Moderna, Inc. , fuboTV Inc., or Pinterest, Inc., I'd be considering selling them right now. Each company's share prices has more than doubled in the past year, blowing past the S&P 500 and its 35% gains during that time. But with inflated valuations and the possibility of a crash looming, they become riskier as each day passes by.\n\nImage source: Getty Images.\n1. Moderna\nModerna has soared by 250% in 12 months, and for good reason -- its COVID-19 vaccine obtained emergency use authorization from the U.S. Food and Drug Administration (FDA) last year. The company expects to generate more than $18 billion in revenue from the vaccine in 2021, and its bottom line will finally be in the black -- in 2020 its losses totaled $747 million, triple what it lost in 2017.\nThings are certainly looking up for Moderna, especially with rival Pfizer looking to get the OK from the FDA for a third dose of its vaccine to help fight the delta variant. If Pfizer is successful, it's likely Moderna would follow suit, which could bring in even more revenue for the company. But there's no certainty that will happen. And more vaccines could be coming to market soon, including one from Novavax, which plans to apply for authorization from the FDA during the third quarter.\nAs countries have more options for vaccines, that will inevitably bring down the revenue and potential market share for Moderna. And beyond that, there are questions about what the future holds for Moderna after COVID-19. While its mRNA technology has proven to be effective, that doesn't guarantee that other vaccines in its pipeline will succeed. Its vaccine for cytomegalovirus, currently the furthest along, is entering phase 3 trials. With a peak annual revenue potential of between $2 billion and $5 billion, however, the company won't be able to solely rely on it in replacing COVID-19-related revenue.\nModerna's future is a question mark for me, and while its forward price-to-earnings ratio of 11 looks cheap, that could change drastically post-COVID. Even on a forward basis, the stock is trading at more than 6 times revenue -- Pfizer is at just 3. Although Moderna is doing well right now, its stock is expensive and could be due for a correction soon.\n2. fuboTV\nStreaming and entertainment company fuboTV isn't profitable, nor does profitability look to be in its sights. But that hasn't stopped investors from jumping on its bandwagon, driving shares up by more than 160% in 12 months. Its subscriber base as of March 31 topped 590,000 people -- a year-over-year increase of 105%. And the company may continue attracting more subscribers thanks to plans to launch a sportsbook before the end of the year.\nHowever, while the company is growing fast, my concern is that its approach may be too aggressive in pursuing revenue. In its most recent quarterly results, for the period ending March 31, revenue of $120 million was nowhere near enough to cover its $185 million in operating expenses. Of particular concern is that fuboTV has incurred subscriber-related expenses of $113 million -- more than the $107 million it brought in from subscription-related revenue.\nWithout good margins to support the company's growth, the problem for investors is that fuboTV's financials may not get stronger as it expands, which could lead to an inevitable need to raise cash -- diluting existing shareholders. fuboTV currently trades at a multiple of 6 times its revenue, and although that's cheaper than Netflix's multiple of more than 9, the streaming giant is at least profitable. In a crash, investors look for safety, and without a strong bottom line, fuboTV's stock could fall quickly.\n3. Pinterest\nPinterest's stock has benefited from people staying at home during the pandemic and using its discovery engine to explore hobbies and interests. As of the end of March, the company had 478 million monthly active users (MAUs), an increase of 30% year over year. That tops last year's results, in which MAUs of 367 million grew by 26%. The company does expect to see a slowdown next quarter, however, with its MAU growth rate likely to be in the \"mid-teens.\"\nEven with the rising user base and a 78% year-over-year increase in sales this past quarter to $485 million, the company still posted a net loss of $22 million. Although that was a fraction of the $141 million loss it incurred a year earlier, with the economy opening back up and people going back to their regular habits, there may be less time to spend on Pinterest -- and a decline in MAUs. If that happens, the progress the company has been making on its bottom line could be stalled.\nPinterest has been a hot stay-at-home stock, but now could become a risky buy given its hefty valuation; currently, the growth stock trades at more than 22 times its revenue -- the average holding in the Technology Select Sector SPDR Fund trades at a multiple of less than 7.","news_type":1},"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808748076,"gmtCreate":1627612773295,"gmtModify":1703493371821,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":14,"repostSize":0,"link":"https://ttm.financial/post/808748076","repostId":"2155188062","repostType":4,"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808883150,"gmtCreate":1627568744270,"gmtModify":1703492597045,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":10,"repostSize":0,"link":"https://ttm.financial/post/808883150","repostId":"1191327663","repostType":4,"isVote":1,"tweetType":1,"viewCount":822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173356866,"gmtCreate":1626621020855,"gmtModify":1703762404343,"author":{"id":"3573200239055289","authorId":"3573200239055289","name":"AK03","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/173356866","repostId":"1183956332","repostType":4,"repost":{"id":"1183956332","pubTimestamp":1626568120,"share":"https://www.laohu8.com/m/news/1183956332?lang=&edition=full","pubTime":"2021-07-18 08:28","market":"us","language":"en","title":"US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1183956332","media":"renaissancecap...","summary":"The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.The largest deal of the week, specialty insurance brokerage Ryan Specialty Group plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in t","content":"<p>The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.</p>\n<p>The largest deal of the week, specialty insurance brokerage&nbsp;<b>Ryan Specialty Group</b>(RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in the 1Q21, the company will be leveraged post-IPO.</p>\n<p>Water infrastructure company&nbsp;<b>Core &amp; Main</b>(CNM) plans to raise $750 million at a $5.2 billion market cap in a 100% synthetic secondary offering. Profitable with solid growth, the company distributes water infrastructure products that connect 4,500 suppliers to over 60,000 municipal, non-residential, and residential customers.</p>\n<p>HR software provider&nbsp;<b>Paycor HCM</b>(PYCR) plans to raise $361 million at a $3.4 billion market cap. Paycor provides human capital management software to small and mid-sized businesses, covering the payroll process and key HR functionality. While net revenue retention fell in the FY20, the company is targeting a large addressable market and has a track record of profitability.</p>\n<p>Latin <a href=\"https://laohu8.com/S/AFG\">American</a> e-commerce platform&nbsp;<b><a href=\"https://laohu8.com/S/VTEX\">VTEX</a></b>(VTEX) plans to raise $304 million at a $3.2 billion market cap. VTEX operates a business-to-consumer e-commerce platform to enterprise customers that natively combines commerce, order management, and marketplace functionality. The company has demonstrated growth, though investments in SG&amp;A and R&amp;D have weighed on profits.</p>\n<p>Learning management platform&nbsp;<b>Instructure Holdings</b>(INST) plans to raise $250 million at a $2.9 billion market cap. The company provides a next-generation Learning Management System (LMS), assessments for learning, actionable analytics, and dynamic content. Instructure states that it is the LMS market leader in both Higher Education and paid K-12, with over 6,000 global customers across 90 countries.</p>\n<p>Protein discovery and development platform&nbsp;<b>AbSci</b>(ABSI) plans to raise $200 million at a $1.6 billion market cap. AbSci currently has nine active programs across seven partners, which include <a href=\"https://laohu8.com/S/MRK\">Merck</a> and Astellas, for which it has either negotiated or plans to negotiate license agreements. The company is highly unprofitable, and 90% of its tech development revenue came from a single partner in the 1Q21.</p>\n<p>Organic beverage brand&nbsp;<b><a href=\"https://laohu8.com/S/ZVIA\">Zevia PBC</a></b>(ZVIA) plans to raise $200 million at a $1.0 billion market cap. Zevia provides six product lines of zero calorie, zero sugar, naturally sweetened beverages in the US and Canada. The company has demonstrated growth and achieved profitability in the 1Q21.</p>\n<p>Content marketing platform&nbsp;<b>Outbrain</b>(OB) plans to raise $200 million at a $1.5 billion market cap. Outbrain’s platform enables over 7,000 online properties, helping them engage their users and monetize their visits by gathering over 1 billion data events each minute. Profitable with strong growth, the company had over 20,000 advertisers using its platform in 2020.</p>\n<p>Fitness franchisor&nbsp;<b>Xponential Fitness</b>(XPOF) plans to raise $200 million at a $711 million market cap. Xponential Fitness is the largest boutique fitness franchisor in the US with over 1,750 studios operating across nine distinct brands. While the company’s business was impacted by the pandemic in 2020, preliminary results for the 2Q21 show 60%+ revenue growth and adjusted EBITDA swinging positive.</p>\n<p>Legal software provider&nbsp;<b>CS Disco</b>(LAW) plans to raise $193 million at a $1.6 billion market cap. Fast growing and unprofitable, DISCO provides a cloud-native, AI-powered legal solution that simplifies ediscovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments.</p>\n<p>Following its postponement in May, Brazil’s&nbsp;<b>Zenvia</b>(ZENV) plans to raise $162 million at a $548 million market cap. The company’s software platform facilitated the flow of communication for more than 10,190 customers throughout Latin America as of March 31, 2021. While it achieved a net revenue expansion rate of nearly 110%, Zenvia’s EBITDA turned negative in the 1Q21.</p>\n<p><b>Couchbase</b>(BASE) plans to raise $151 million at a $992 million market cap. Couchbase provides a NoSQL database that enables enterprises and developers to build and run applications across the cloud, on-premise, hybrid, or mobile and edge environments. The company has a sticky customer base that includes 30% of the Fortune 100, though it remains unprofitable due to high S&amp;M costs.</p>\n<p>Following its postponement in April,<b>Kaltura</b>(KLTR) plans to raise $150 million at a $1.4 billion market cap. Kaltura provides live, real-time, and on-demand video products to a wide range of businesses including educational institutions, and media and telecom companies. Thanks to the growing adoption of virtual events, the company saw revenue expand in the 1Q21, though gross margin contracted.</p>\n<p><b>Gambling.com Group</b>(GAMB) plans to raise $90 million at a $435 million market cap. Gambling.com Group is a performance marketing company and a digital marketing services provider active exclusively in the online gambling industry, with a principal focus on iGaming and sports betting. Profitable and fast growing, the company has increased its customer base from 131 in 2017 to over 200 in 2020.</p>\n<p>Three biotechs are expected to round out the week: cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL), which plans to raise $85 million at a $398 million market cap; preclinical biotech&nbsp;<b>Ocean Biomedical</b>(OCEA), which plans to raise $50 million at a $506 million market cap; and cancer biotech&nbsp;<b>Elicio Therapeutics</b>(ELTX), which plans to raise $40 million at a $201 million market cap.</p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-18 08:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.\nThe largest deal of the week, specialty insurance brokerage Ryan ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CNM":"Core & Main, Inc.","OB":"Outbrain Inc.","INST":"Instructure Holdings, Inc.","PYCR":"Paycor HCM, Inc.","GAMB":"Gambling.com Group Limited","CADL":"Candel Therapeutics, Inc.","LAW":"CS Disco, Inc.","BASE":"Couchbase, Inc.","ZVIA":"Zevia PBC","OCEA":"Ocean Biomedical","VTEX":"VTEX","ABSI":"Absci Corporation.","RYAN":"Ryan Specialty Group Holdings, Inc.","ELTX":"Elicio Therapeutics"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183956332","content_text":"The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.\nThe largest deal of the week, specialty insurance brokerage Ryan Specialty Group(RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in the 1Q21, the company will be leveraged post-IPO.\nWater infrastructure company Core & Main(CNM) plans to raise $750 million at a $5.2 billion market cap in a 100% synthetic secondary offering. Profitable with solid growth, the company distributes water infrastructure products that connect 4,500 suppliers to over 60,000 municipal, non-residential, and residential customers.\nHR software provider Paycor HCM(PYCR) plans to raise $361 million at a $3.4 billion market cap. Paycor provides human capital management software to small and mid-sized businesses, covering the payroll process and key HR functionality. While net revenue retention fell in the FY20, the company is targeting a large addressable market and has a track record of profitability.\nLatin American e-commerce platform VTEX(VTEX) plans to raise $304 million at a $3.2 billion market cap. VTEX operates a business-to-consumer e-commerce platform to enterprise customers that natively combines commerce, order management, and marketplace functionality. The company has demonstrated growth, though investments in SG&A and R&D have weighed on profits.\nLearning management platform Instructure Holdings(INST) plans to raise $250 million at a $2.9 billion market cap. The company provides a next-generation Learning Management System (LMS), assessments for learning, actionable analytics, and dynamic content. Instructure states that it is the LMS market leader in both Higher Education and paid K-12, with over 6,000 global customers across 90 countries.\nProtein discovery and development platform AbSci(ABSI) plans to raise $200 million at a $1.6 billion market cap. AbSci currently has nine active programs across seven partners, which include Merck and Astellas, for which it has either negotiated or plans to negotiate license agreements. The company is highly unprofitable, and 90% of its tech development revenue came from a single partner in the 1Q21.\nOrganic beverage brand Zevia PBC(ZVIA) plans to raise $200 million at a $1.0 billion market cap. Zevia provides six product lines of zero calorie, zero sugar, naturally sweetened beverages in the US and Canada. The company has demonstrated growth and achieved profitability in the 1Q21.\nContent marketing platform Outbrain(OB) plans to raise $200 million at a $1.5 billion market cap. Outbrain’s platform enables over 7,000 online properties, helping them engage their users and monetize their visits by gathering over 1 billion data events each minute. Profitable with strong growth, the company had over 20,000 advertisers using its platform in 2020.\nFitness franchisor Xponential Fitness(XPOF) plans to raise $200 million at a $711 million market cap. Xponential Fitness is the largest boutique fitness franchisor in the US with over 1,750 studios operating across nine distinct brands. While the company’s business was impacted by the pandemic in 2020, preliminary results for the 2Q21 show 60%+ revenue growth and adjusted EBITDA swinging positive.\nLegal software provider CS Disco(LAW) plans to raise $193 million at a $1.6 billion market cap. Fast growing and unprofitable, DISCO provides a cloud-native, AI-powered legal solution that simplifies ediscovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments.\nFollowing its postponement in May, Brazil’s Zenvia(ZENV) plans to raise $162 million at a $548 million market cap. The company’s software platform facilitated the flow of communication for more than 10,190 customers throughout Latin America as of March 31, 2021. While it achieved a net revenue expansion rate of nearly 110%, Zenvia’s EBITDA turned negative in the 1Q21.\nCouchbase(BASE) plans to raise $151 million at a $992 million market cap. Couchbase provides a NoSQL database that enables enterprises and developers to build and run applications across the cloud, on-premise, hybrid, or mobile and edge environments. The company has a sticky customer base that includes 30% of the Fortune 100, though it remains unprofitable due to high S&M costs.\nFollowing its postponement in April,Kaltura(KLTR) plans to raise $150 million at a $1.4 billion market cap. Kaltura provides live, real-time, and on-demand video products to a wide range of businesses including educational institutions, and media and telecom companies. Thanks to the growing adoption of virtual events, the company saw revenue expand in the 1Q21, though gross margin contracted.\nGambling.com Group(GAMB) plans to raise $90 million at a $435 million market cap. Gambling.com Group is a performance marketing company and a digital marketing services provider active exclusively in the online gambling industry, with a principal focus on iGaming and sports betting. Profitable and fast growing, the company has increased its customer base from 131 in 2017 to over 200 in 2020.\nThree biotechs are expected to round out the week: cancer biotech Candel Therapeutics(CADL), which plans to raise $85 million at a $398 million market cap; preclinical biotech Ocean Biomedical(OCEA), which plans to raise $50 million at a $506 million market cap; and cancer biotech Elicio Therapeutics(ELTX), which plans to raise $40 million at a $201 million market cap.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}